SteadyMed Demonstrat
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
December 07, 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
SteadyMed Announces
SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting
October 28, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed Files Inte
SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
October 21, 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed to Partici
SteadyMed to Participate in Upcoming Investor Conferences
September 02, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Provide
SteadyMed to Provide Insights on Recent Corporate Developments and Report Second Quarter 2015 Financial Results
August 06, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Completes
SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
July 07, 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed and Cardio
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
June 29, 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
SteadyMed to Present
SteadyMed to Present at the JMP Securities Life Sciences Conference
June 16, 2015 11:40 ET | SteadyMed Therapeutics
SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed Submits Ap
SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension
May 07, 2015 07:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug...
SteadyMed Appoints D
SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer
April 08, 2015 07:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive...